Preclinical Characterization of the Anti-Leukemia Activity of the CD33/CD16a/NKG2D Immune-Modulating TriNKET

CD33 acute myeloid leukemia (AML) immunotherapy natural killer (NK) cell trispecific antibody

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
22 Feb 2024
Historique:
received: 22 01 2024
revised: 11 02 2024
accepted: 20 02 2024
medline: 13 3 2024
pubmed: 13 3 2024
entrez: 13 3 2024
Statut: epublish

Résumé

Increasing efforts are focusing on natural killer (NK) cell immunotherapies for AML. Here, we characterized CC-96191, a novel CD33/CD16a/NKG2D immune-modulating TriNKET

Identifiants

DOI: 10.3390/cancers16050877 PMID: 38473239
pubmed: 38473239
pii: cancers16050877
doi: 10.3390/cancers16050877
pii:
doi:

Banques de données

ClinicalTrials.gov
['NCT04789655']

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : Celgene/Bristol Myers Squibb
ID : Sponsored Research Agreement

Auteurs

Margaret C Lunn-Halbert (MC)

Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.
ORCID: 0000-0003-0527-5575

George S Laszlo (GS)

Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.

Sarah Erraiss (S)

Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.

Mark T Orr (MT)

Immuno-Oncology Cellular Therapy Thematic Research Center, Bristol Myers Squibb, Seattle, WA 98109, USA.

Heidi K Jessup (HK)

Immuno-Oncology Cellular Therapy Thematic Research Center, Bristol Myers Squibb, Seattle, WA 98109, USA.

Heather J Thomas (HJ)

Immuno-Oncology Cellular Therapy Thematic Research Center, Bristol Myers Squibb, Seattle, WA 98109, USA.

Henry Chan (H)

Bristol Myers Squibb, San Diego, CA 92121, USA.

Mahan A Jahromi (MA)

Bristol Myers Squibb, San Diego, CA 92121, USA.

Jonathan Lloyd (J)

Bristol Myers Squibb, San Diego, CA 92121, USA.

Ann F Cheung (AF)

Dragonfly Therapeutics, Waltham, MA 02451, USA.

Gregory P Chang (GP)

Dragonfly Therapeutics, Waltham, MA 02451, USA.

Tanmay Dichwalkar (T)

Dragonfly Therapeutics, Waltham, MA 02451, USA.
ORCID: 0000-0003-1095-2059

Daniel Fallon (D)

Dragonfly Therapeutics, Waltham, MA 02451, USA.

Asya Grinberg (A)

Dragonfly Therapeutics, Waltham, MA 02451, USA.

Eduardo Rodríguez-Arbolí (E)

Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.
Department of Hematology, Hospital Universitario Virgen del Rocío, Instituto de Biomedicina de Sevilla (IBIS/CSIC/CIBERONC), University of Seville, 41013 Seville, Spain.

Sheryl Y T Lim (SYT)

Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.
ORCID: 0000-0002-2606-9220

Allie R Kehret (AR)

Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.

Jenny Huo (J)

Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.

Frances M Cole (FM)

Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.

Samuel C Scharffenberger (SC)

Molecular Medicine and Mechanisms of Disease (M3D) Ph.D. Program, University of Washington, Seattle, WA 98195, USA.
ORCID: 0000-0001-5905-8862

Roland B Walter (RB)

Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.
Department of Medicine, Division of Hematology and Oncology, University of Washington, Seattle, WA 98195, USA.
Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA 98195, USA.
ORCID: 0000-0002-9268-3341

Classifications MeSH